




(Incorporated in the Cayman Islands with Limited Liability)

Stock Code: 0575

19 December 2017

ANNOUNCEMENT




Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

MANUFACTURING UPDATE

We refer to the Company's announcements dated 3 and 24 October 2017 (the "**Company Announcements**").

Unless the context otherwise requires, capitalised terms used in this announcement shall have the same meaning given to them in the Company Announcements.

The Company is pleased to announce that on 18 December 2017 (after market close in Hong Kong) the Group received confirmation from PSNW, the manufacturer of Fortacin™, that an aggregate total of not less than three process validation batches manufactured at 300 litre scale comply with the currently registered release specification indicating validation of manufacture at such scale. In accordance with the Amended and Restated Licence Agreement and as foreshadowed in the Company Announcements, it now follows that following the first commercial sale of Fortacin™ in each of France, Germany, Italy, Portugal and Spain, scheduled for March 2018, a total of €4 million (or approximately US\$4.70 million or HK\$36.66 million) will be due from Recordati to the Group without any withholding of the €1 million (or approximately US\$1.17 million or HK\$9.13 million) previously possible should the three manufactured batches at 300 litre scale have come back out of specification.



With the process validation of the manufacturing batches at 300 litre scale, the Group and its commercial partners now have satisfied yet another important milestone in the lead-up to commercial launch in Continental Europe, and have importantly now made commercially viable improved economics from the larger scale manufacture now possible for Fortacin™.

The Company is also pleased to inform shareholders that PSNW commenced manufacturing of Recordati's initial launch orders of Fortacin™ last week in anticipation of meeting Recordati's initial launch in France, Germany, Italy, Spain and Portugal in March 2018 followed by the launch in Greece, Romania, Czech Republic, Slovak Republic and Poland in the second half of 2018 and in the rest of Europe, Russia, the Commonwealth of Independent States and select countries of North Africa in the coming years.

The Group will continue to keep shareholders and potential investors updated on developments leading up to commercial launch of Fortacin™ in Continental Europe.

Note: Unless otherwise specified herein, amounts denominated in: (i) EUR have been translated, for the purpose of illustration only, into US\$ using the exchange rate of EUR 1.00 = US\$1.1748; and (ii) US\$ have been translated, for the purpose of illustration only, into HK\$ using the exchange rate of US\$1.00 = HK\$7.80.

On Behalf of the Board of
Regent Pacific Group Limited

Jamie Gibson
Director

Directors of the Company:

James Mellon (*Chairman*)^{*}

Jamie Gibson (*Chief Executive Officer*)

David Comba[#]

Julie Oates[#]

Mark Searle[#]

Jayne Sutcliffe^{*}

^{*} *Non-Executive Directors*

[#] *Independent Non-Executive Directors*

Hong Kong, 19 December 2017